An interventional study of Inositol + Folic acid and Folic acid in Polycystic Ovary Syndrome, sponsored by Università degli Studi dell'Insubria. Not yet recruiting. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-05.
Sponsored by Università degli Studi dell'Insubria · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing inositol in Polycystic Ovary Syndrome — 5 open to participants now, 6 under way, 1 of them phase 3. Inositol · Polycystic Ovary Syndrome.
Among the 33 studies testing inositol in Polycystic Ovary Syndrome, this one is the 14th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2022, is one of 19 with no phase, and was the 13th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →5 of the 33 studies testing inositol in Polycystic Ovary Syndrome are open now, in 4 countries. Recruiting first, the newest first:
Istanbul Health and Technology University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18–35 · Women only
American University of Beirut Medical Center · Sites in Lebanon
Ages 18–18 · Women only · Healthy volunteers
Fatima Tariq · Sites in Pakistan
Ages 16–45 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 73 across the 32 interventional studies. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
Università degli Studi dell'Insubria is the lead sponsor of 68 studies on the registry; 8 are open to participants now.
Università degli Studi dell'Insubria has 2 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies testing inositol in Polycystic Ovary Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03059173Phase 3University Hospital, LilleInterest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome | 2027-09-12 |
| NCT07896642Istanbul Health and Technology UniversityBrown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography | 2026-12 |
| NCT07604779Beni-Suef UniversityEnhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection | 2026-12-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies testing inositol in Polycystic Ovary Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovarian syndrome (PCOS) is a heterogeneous, multifaceted and complex disorder characterized by insulin resistance (IR), hyperinsulinemia, and hyperandrogenism leading ovarian disfunction and infertility. Given the central pathogenic role of IR in the endocrine, reproductive, and metabolic disturbances of PCOS, several pharmacological and non-pharmacological approaches have been proposed to counteract the hyper insulinemic IR typical of the syndrome. Two Inositol stereoisomers, Myo-Inositol (MI) and D-chiro-inositol (DCI), captured the attention of researchers for their insulin-sensitizing actions, which configure them as proper candidates for the treatment of PCOS.
Very few studies reported on spontaneous clinical pregnancy rates, none were powered for this outcome, and none reported on the clinically relevant outcome of live birth. Therefore, data about clinical pregnancy rate, live birth rate, and miscarriage rate comparing inositols with placebo are limited.
Nevertheless, regarding infertility the primary outcomes that should be considered are clinical pregnancy rate, miscarriage rate and live birth rate. Although many studies showed improved hormonal and metabolic profile and improved ovulation rate and higher quality and number of oocyte retrieved in Assisted Reproductive Technology (ART) in PCOS women after inositols administration, data about clinical pregnancy rate, live birth rate, and miscarriage rate are limited with several concerns regarding interpretation of the studies.
Furthermore, independently by the effect on PCOS related infertility, few data are available about the role of inositol on obstetrics outcomes of pregnancies conceived after treatment with inositol and/or orally supplemented during pregnancy. Considering that the combination of MI and DCI alleviate many of the metabolic dysregulations typical of PCOS thanks to insulin-sensitizing actions, it is plausible consider a beneficial effects on pregnancy complications such as gestational diabetes and preeclampsia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
Dietary Supplement: Inositol + Folic acid
Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
Dietary Supplement: Folic acid
Drug pages: InositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Folic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Daily oral supplementation before spontaneous conception until delivery: Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg
Daily oral supplementation before spontaneous conception until delivery: Folic acid: 400 mcg
Gestational diabetes prevalence
Gestational diabetes prevalence: number of women that develop gestational diabetes diagnosed based on oral glucose tolerance test (OGTT) cut-off (92 - 180 - 153 mg/dl).
Time frame: During pregnancy at 16-18 week or 24-28 weeks as recommended
Preeclampsia prevalence
Preeclampsia prevalence: number of women that develop preeclampsia diagnosed based on blood pressure higher than 140/90 mmHg after 20 week of gestation plus 24h proteinuria higher that 300mg.
Time frame: During pregnancy after the 20 week of gestation
Birth weight
gr
Time frame: At delivery.
Weight gain in pregnancy
Kg
Time frame: Change in weight before pregnancy and at the 38 week of gestation
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2022; primary completion for Dec 2024, 35 months later.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 35 months is above that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Inositol · Folic Acid
Università degli Studi dell'Insubria